Brought to you by 
Johnson & Johnson partners with MD Anderson
03 Mar 2023
Executive Summary
Johnson & Johnson signed a three-year agreement under which Johnson & Johnson Innovation LLC and Janssen Biotech Inc. will work with the University of Texas’ MD Anderson Cancer Center’s Moon Shots Program to develop immunology-based oncology therapeutics. The partners will work in undisclosed areas of interest to Janssen.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Johnson & Johnson partners with MD Anderson
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice